Compare ATKR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATKR | WVE |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2016 | 2015 |
| Metric | ATKR | WVE |
|---|---|---|
| Price | $56.33 | $12.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $75.67 | $31.47 |
| AVG Volume (30 Days) | 243.7K | ★ 2.1M |
| Earning Date | 05-04-2026 | 05-29-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $2,850,378,000.00 | $3,704,000.00 |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $3.94 | $119.93 |
| P/E Ratio | $127.64 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $49.92 | $5.28 |
| 52 Week High | $80.06 | $21.73 |
| Indicator | ATKR | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 42.11 |
| Support Level | $55.25 | $12.53 |
| Resistance Level | $66.25 | $15.02 |
| Average True Range (ATR) | 2.00 | 0.82 |
| MACD | -0.75 | -0.08 |
| Stochastic Oscillator | 10.92 | 6.46 |
Atkore Inc is a manufacturer of Electrical products for the non-residential construction and renovation markets, as well as residential markets, and Safety & Infrastructure products for the construction and industrial markets. The Electrical segment manufactures products used in the construction of electrical power systems including conduit, cable, and installation accessories. This segment serves contractors in partnership with the electrical wholesale channel. The Safety & Infrastructure segment designs and manufactures solutions including metal framing, mechanical pipe, perimeter security, and cable management. These solutions are marketed to contractors, original equipment manufacturers (OEMs), and end-users. The majority of revenue is generated from the Electrical segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.